| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 12/13/2001 | WO2001093883A1 Therapeutic agents - iii |
| 12/13/2001 | WO2001093879A1 Biologically active agents and drugs |
| 12/13/2001 | WO2001093871A1 Reangiostenosis preventives |
| 12/13/2001 | WO2001093870A1 Remedies for diseases caused by fibrin formation and/or endothelial cell damage |
| 12/13/2001 | WO2001093867A1 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors |
| 12/13/2001 | WO2001093862A1 Prostaglandin compounds for treating congestive heart failure |
| 12/13/2001 | WO2001093849A2 Treatment of gastroesophageal reflux disease using piperidine derivatives |
| 12/13/2001 | WO2001093847A2 Compositions, kits, and methods for promoting defined health benefits |
| 12/13/2001 | WO2001093845A2 Carboxyalkylether-acat inhibitor combinations |
| 12/13/2001 | WO2001093841A2 Barbituric acid analogs as therapeutic agents |
| 12/13/2001 | WO2001093833A2 Kits and methods for optimizing the efficacy of chondroprotective compositions |
| 12/13/2001 | WO2001093806A2 HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS |
| 12/13/2001 | WO2001085145A8 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| 12/13/2001 | WO2001072772A3 Calcium binding regulatory subunit |
| 12/13/2001 | WO2001055103A3 Chimeric neuropeptide y receptors |
| 12/13/2001 | WO2001044200A3 Selective neurokinin antagonists |
| 12/13/2001 | WO2001041709A3 Methods for treating cell death diseases and inflammation |
| 12/13/2001 | WO2001040243A3 Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives |
| 12/13/2001 | WO2001039742A3 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 12/13/2001 | WO2001037820A3 Ionizable indolinone derivatives and their use as ptk ligands |
| 12/13/2001 | WO2001027136A3 Peptides which stimulate the immune response and tissue regeneration |
| 12/13/2001 | WO2001026682A3 Modified plant viruses and methods of use thereof |
| 12/13/2001 | WO2001021157A3 Local delivery of 17-beta estradiol for preventing vascular intima hyperplasia and for improving vascular endothelium function after vascular injury |
| 12/13/2001 | WO2001019376A3 METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS |
| 12/13/2001 | WO2001011038A3 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| 12/13/2001 | WO2000044888A3 Dimethylarginine dimethylaminohydrolases |
| 12/13/2001 | WO2000029501A9 Radioactive coating solutions, methods, and substrates |
| 12/13/2001 | US20010051735 Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance |
| 12/13/2001 | US20010051656 Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction |
| 12/13/2001 | US20010051626 Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| 12/13/2001 | US20010051623 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic |
| 12/13/2001 | US20010051612 Vasodilation; using 2-adenosine propargyl phenyl ether |
| 12/13/2001 | US20010051595 Injection into blood |
| 12/13/2001 | CA2810249A1 Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2700312A1 An improved method for extracting cocoa procyanidins |
| 12/13/2001 | CA2413906A1 Carboxyalkylether-acat inhibitor combinations |
| 12/13/2001 | CA2412436A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2412377A1 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | CA2411762A1 Method for obtaining characterised muscle-derived cell populations and uses |
| 12/13/2001 | CA2411596A1 Therapeutic agents - ii |
| 12/13/2001 | CA2411473A1 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 12/13/2001 | CA2411396A1 Hmg coa reductase inhibitors for promoting angiogenesis |
| 12/13/2001 | CA2411351A1 Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors |
| 12/13/2001 | CA2411139A1 Inhibitors of c-reactive protein induced inflammation |
| 12/13/2001 | CA2411069A1 The human voltage gated sodium channel .beta.-1a subunit and methods of use |
| 12/13/2001 | CA2411062A1 Benzamide ligands for the thyroid receptor |
| 12/13/2001 | CA2411013A1 6-phenylpyrrolopyrimidinedione derivatives |
| 12/13/2001 | CA2411010A1 Tetracyclic diketopiperazine compounds as pdev inhibitors |
| 12/13/2001 | CA2410509A1 Indolinone derivatives as protein kinase/phosphatase inhibitors |
| 12/13/2001 | CA2410458A1 Methods and compositions for inhibiting immunoglobulin-mediated__reperfusion injury |
| 12/13/2001 | CA2410158A1 Protein markers for pharmaceuticals and related toxicity |
| 12/13/2001 | CA2409392A1 Intracellular signaling proteins |
| 12/13/2001 | CA2409268A1 Macromolecular drug complexes and compositions containing the same |
| 12/13/2001 | CA2409197A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 12/13/2001 | CA2409015A1 Caspase inhibitors and uses thereof |
| 12/13/2001 | CA2408748A1 Nuclear hormone receptor |
| 12/13/2001 | CA2408611A1 Kits and methods for optimizing the efficacy of chondroprotective compositions |
| 12/13/2001 | CA2408609A1 Compositions, kits, and methods for promoting defined health benefits |
| 12/13/2001 | CA2408542A1 Prostaglandin compounds for treating congestive heart failure |
| 12/13/2001 | CA2381249A1 Methods and compositions for modulating oxidized ldl transport |
| 12/12/2001 | EP1162458A1 Methods and compositions for modulating oxidized LDL transport |
| 12/12/2001 | EP1161948A2 Pharmaceutical or food composition for treatment of brain edema |
| 12/12/2001 | EP1161946A2 Soluble analogs of probucol |
| 12/12/2001 | EP1161944A1 Drugs, foods and oral compositions containing stilbene-type compounds |
| 12/12/2001 | EP1161454A2 Peptides with anti-angiogenic activity |
| 12/12/2001 | EP1161448A1 49 human secreted proteins |
| 12/12/2001 | EP1161447A1 50 human secreted proteins |
| 12/12/2001 | EP1161444A1 A novel inhibitor of programmed cell death |
| 12/12/2001 | EP1161440A1 Method for refolding molecules of polypeptides containing ig domains |
| 12/12/2001 | EP1161433A1 Tyrosine kinase inhibitors |
| 12/12/2001 | EP1161429A2 Heterocyclic compounds as adenosine deaminase inhibitors |
| 12/12/2001 | EP1161422A1 Amine derivatives as protease inhibitors |
| 12/12/2001 | EP1161419A1 Spirocyclic ketones and their use as tachykinin antagonists |
| 12/12/2001 | EP1161415A2 N-cyanomethylamides as protease inhibitors |
| 12/12/2001 | EP1161280A1 Use of an integrin antagonist and a chemotherapeutic agent in the treatment of neoplasia |
| 12/12/2001 | EP1161279A1 Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin |
| 12/12/2001 | EP1161257A2 Pharmaceutical compositions comprising tgf-beta |
| 12/12/2001 | EP1161236A1 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors |
| 12/12/2001 | EP1161235A1 Combinations for the treatment of diseases involving angiogenesis |
| 12/12/2001 | EP1161234A2 Method for delivering benzidine prostaglandins by inhalation |
| 12/12/2001 | EP1161233A2 Lxr modulators |
| 12/12/2001 | EP1161232A1 Hydroxy diphenyl urea sulfonamides as il-8 receptor antagonists |
| 12/12/2001 | EP0983266B1 novel tetrahydroisoquinolin thiophenecarboximidamides |
| 12/12/2001 | EP0938471B1 The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 12/12/2001 | EP0781126B1 Derivatives of 2-amino-1,2,3,4-tetrahydro-naphthalene active on the cardiovascular system |
| 12/12/2001 | EP0766570B1 Methods for treating respiratory disease |
| 12/12/2001 | EP0699075B1 MODIFIED FACTOR VII for inhibiting vascular restenosis and platelet deposition |
| 12/12/2001 | EP0666758B1 Anti-inflammatory tolerogenic and immunoinhibiting properties of carbohydrate binding-peptides |
| 12/12/2001 | EP0589964B1 Method and composition to reduce myocardial reperfusion injury |
| 12/12/2001 | CN1326459A Heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| 12/12/2001 | CN1326458A CRF receptor antagonists and methods relating thereto |
| 12/12/2001 | CN1326457A 4-aminopyrrolopyrimidines as kinase inhibitors |
| 12/12/2001 | CN1326456A 8-Azabicyclo [3.,2.1] Oct-2-Ene and-Octane derivatives |
| 12/12/2001 | CN1326450A Hydroxyflavone derivatives as tau protein kinase inhibitors |
| 12/12/2001 | CN1326443A Fluorinated 3,4-dihydroquinoline derivatives used as NOS inhibitors |
| 12/12/2001 | CN1326361A Methods for detecting, preventing, and treating renal disorders by modulating, regulating and inhibiting connective tissue growth factor |
| 12/12/2001 | CN1326360A Use of enterobacterium protein OMPA for specific targeting towards antigen-presening cells |
| 12/12/2001 | CN1326347A 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens |
| 12/12/2001 | CN1326330A Therapeutic use of polymers |
| 12/12/2001 | CN1325730A Application of alkaline fibroblast growth factor in preparing medicine to prevent and cure cerebral injury |